Relmada Therapeutics, Inc. (RLMD)
| Market Cap | 580.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -43.22M |
| Shares Out | 16.04M |
| EPS (ttm) | -2.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $35.73 |
| Previous Close | $35.49 |
| Change ($) | 0.24 |
| Change (%) | 0.68% |
| Day's Open | 35.17 |
| Day's Range | 34.70 - 36.58 |
| Day's Volume | 61,976 |
| 52-Week Range | 23.78 - 50.12 |
Investors need to pay close attention to Relmada (RLMD) stock based on the movements in the options market lately.
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced th...
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.
NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.
NEW YORK, May 29, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases...
NEW YORK, May 26, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases...
Should investors be excited or concerned about Relmada Therapeutics' attempt to treat severe depression with a variant of methadone?
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2.
Relmada Therapeutics: A Promising Depression Focused Player For 2020
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1.
Relmada Therapeutics Inc. shares RLMD, +141.79% soared 137% Tuesday, after the clinical-stage biotech reported positive results from a midstage trial of a treatment for depression.
About RLMD
Relmada Therapeutics, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesi... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 2004 |
| CEO Sergio Traversa | Employees 6 |
| Stock Exchange NASDAQ | Ticker Symbol RLMD |
Analyst Forecasts
According to 6 analysts, the average rating for RLMD stock is "Strong Buy." The 12-month stock price forecast is 62.83, which is an increase of 75.85% from the latest price.